DermTech to Present at Florida Association of Health Plans 2021 Annual Conference

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it is presenting at the 2021 Florida Association of Health Plans (“FAHP”) annual conference on November 14-16, 2021. DermTech’s Chief Medical Officer, Loren Clarke, MD, will be presenting the precision genomic DermTech Melanoma Test to FAHP’s health plan membership. DermTech became an associate member of FAHP in August 2021 and will introduce its non-invasive melanoma test to FAHP’s health plan membership in a 60-minute webcast on October 5, 2021.

“Melanoma and pigmented lesion assessment are a public health concern in the state of Florida, with nearly 10% of diagnosed cases and 10% of deaths from melanoma occurring each year in the state. Consistent with our continued investment in education of patients and healthcare providers, we recognize the importance of engaging the health plan community to not only introduce the benefits of early detection through objective genomic analyses, but also to highlight the improved outcomes, patient and physician experience, and the economic benefits when using the DermTech Melanoma Test as a triage test to clinically manage patients with pigmented lesions suspicious of melanoma,” said Dr. Clarke.

“We welcome DermTech as a new associate member and look forward to its participation in the October 5 webinar series and presentation at our annual conference this November,” said FAHP Spokesperson. “Our association provides a platform to connect our health plan membership with the provider community to facilitate collaboration, education, and advocacy which aligns with our mission to improve and protect the health and financial security of Florida families and business community.”

About DermTech

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

Forward-looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including the Smart Sticker platform, and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005750/en/